ESSA Pharma Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ESSA Pharma stock.
View analyst ratings for ESSA Pharma or view top-rated stocks.

Wall Street analysts have given ESSA Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ESSA Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ESSA Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for ESSA Pharma.

ESSA Pharma Inc. (NASDAQ:EPIX) posted its earnings results on Thursday, May, 6th. The company reported ($0.36) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.15.
View ESSA Pharma's earnings history.

ESSA Pharma's stock was trading at $4.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EPIX shares have increased by 570.5% and is now trading at $27.29.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued 12-month price objectives for ESSA Pharma's shares. Their forecasts range from $17.00 to $50.00. On average, they anticipate ESSA Pharma's stock price to reach $33.75 in the next year. This suggests a possible upside of 23.7% from the stock's current price.
View analysts' price targets for ESSA Pharma or view top-rated stocks among Wall Street analysts.

Some companies that are related to ESSA Pharma include Agios Pharmaceuticals (AGIO), Intra-Cellular Therapies (ITCI), Emergent BioSolutions (EBS), Cassava Sciences (SAVA), Sage Therapeutics (SAGE), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Insmed (INSM), Rocket Pharmaceuticals (RCKT), Taro Pharmaceutical Industries (TARO), Cryoport (CYRX), Dicerna Pharmaceuticals (DRNA), IGM Biosciences (IGMS), Amicus Therapeutics (FOLD) and Pacira BioSciences (PCRX).
View all of EPIX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX).

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

ESSA Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BVF Inc. IL (8.61%), Vivo Capital LLC (6.12%), Bellevue Group AG (5.41%), Janus Henderson Group PLC (4.49%), Boxer Capital LLC (2.03%) and Morgan Stanley (1.70%).
View institutional ownership trends for ESSA Pharma.

EPIX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Omega Fund Management LLC, Silverarc Capital Management LLC, and Millennium Management LLC.
View insider buying and selling activity for ESSA Pharma or view top insider-selling stocks.

EPIX stock was bought by a variety of institutional investors in the last quarter, including Bellevue Group AG, Janus Henderson Group PLC, Boxer Capital LLC, Rock Springs Capital Management LP, Sectoral Asset Management Inc, Frazier Management LLC, Acuta Capital Partners LLC, and Ally Bridge Group NY LLC.
View insider buying and selling activity for ESSA Pharma or or view top insider-buying stocks.

Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EPIX stock can currently be purchased for approximately $27.29.

ESSA Pharma has a market capitalization of $921.86 million. The company earns $-23,440,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

ESSA Pharma employs 25 workers across the globe.

The official website for ESSA Pharma is www.essapharma.com.

ESSA Pharma is headquartered at 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5.

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962 or via email at [email protected]